1 / 27

Myocardial Protection

Myocardial Protection. Eugene Yevstratov , MD Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation Buenos Aires, Argentina October/2002. Goals of Myocardial protection. 1. Protect against ischemic injury. 2. Provide a motionless, bloodless field

morela
Download Presentation

Myocardial Protection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myocardial Protection Eugene Yevstratov, MD Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation Buenos Aires, Argentina October/2002

  2. Goals of Myocardial protection 1.Protect against ischemic injury 2.Provide a motionless, bloodless field 3.Allow effective post-ischemic myocardial resuscitation

  3. Spectrum of myocardial ischemic injury • Acute ischemic disfunction • Preconditioning • Stunning • Hibernation • Necrosis vs. Apoptosis

  4. Acute ischemic disfunction • Reversible contractile failure • Perfusion pressure • O2 supply • Inmediate recovery

  5. Preconditioning • Reversible • Slowed energy utilization • Reduction in myocardial necrosis • Increase protective abilities of myocardium • Presented as a normal proper protective reaction of the ischemic myocardium • Recovery Hs,Ds

  6. Stunning • Parcialy Reversible • May be accompained by endothelial disfunction (NO) causing reduced coronary blood flow • Result of ischemia-reperfusion insult • Mediated by increased intracellular Ca accumulation • Recovery in Hs,Wks

  7. Hibernation • Parcialy Reversible • Related to poor myocardial blood flow • Chronic • Recovery Wks,Mo

  8. Necrosis • Irreversible • Hyper contracture - “contracture band necrosis”, “stone heart” • Osmotic/ionic dysregulation, membrane injury • Cell swelling&disruption • Lysis

  9. Apoptosis • Irreversible • Death signal • Cell shrinkage • Cytoplasmic and nuclear condensation • Phagocytosis

  10. Systems involved into membrane injury • MAC( membrane attack complex) • Adenosine dependent receptors • K+ATP dependent chanels • NHE(sodium hydrogen exchanger)

  11. Cellular effects of ischemia • Altered membrane potential • Altered ion distribution(increase intracellularCa++/Na++) • Cellular swelling • Cytoskeletal Disorganisation • Increased hypoxantine • Decreased ATP • Decreased phosphocreatine • Decreased Glutatione • Cellular Acidosis

  12. Straqtegies for Heart protection • Increase the O2 offer • Decreae oxygen demand • Methabolical intervention • Prevention of demand increased • Substrate disponsability

  13. Myocardial O2 consumptions at 37C • Beating (full,perfused) 10ml/100gr/min • Beating (empty,perfused) 5,5ml/100gr/min • Fibrilating(empty,perfused) 6,5ml/100gr/min • K+ Cardioplegia(empty,crossclamp) 1,0ml/100gr/min

  14. Myocardial O2 consumptionml/100gr/min • Temperatura C 37 32 28 22 Beating (empty) 5,5 5,0 4,0 2,9 Fibrilating (empty) 6,5 3,8 3,0 2,0 K+ cardioplegia 1,0 0,8 0,6 0,3

  15. Cardioplegia - Options No cardioplegia Cardioplegia Type ( blood vs crystalloid, cont vs intermittent ) Route ( antegrade vs retrograde ) Temperature ( warm vs cold ) Additives Special consideration ( Acute infarction, Neonate)

  16. Rivero Cardioplegia solutions 1 2

  17. Mechanism of Cardioplegic Protection • Mechanical arrest ( K – induced, 80% reduction in O2 consumption) • Hypotermia (10-15% furter reduction in O2 consumption) • Aerobic metabolism – oxygenated cardioplegia • Maintain hypotermic arrest with readministration every 15-20 min • Retrograde delivery LV RV protection

  18. Protect from rewarming Systemic hypotermia Aortic/ventricular vents Total bypass (caval oclusion) Acute Ischemia Waqrm induction Substrate enhancement Controlled reperfusion Warm,hypocalcemic,alkaline cardioplegia Retrograde or low flow-pressure antegrade perfusion Energy replacement while arrested Uniform warming Other consideration

  19. Cardioplegic Composition • Blood vs Crystalloid • Buffers • Calcium • Potassium • Free radical scavengers • Others

  20. Blood vs Crystalloid O2 carrying capacity ( Hematocrit 15 – 20 %) Buffers –histidine Free radical scavengers in RBCs Improved rheologic / oncotic properties Metabolic substrate

  21. Buffers THAM Histidine NaHCO3 Slightly alkaline reperfusion

  22. Calcium, Potassium Small amounts of calcium ( 0.1 – 0.5 mM/L ) Ca chelated in blood with citrate 10 – mM/L of potassium ( first dose highest ) > 30 mM/L – endothelial dysfunction

  23. Free radical scavengers.Others Allopurinol Propofol Deferoxamine Metabolic substrates ( adenosine, nucleotid transport inhibitors...) K- channel openers ( Nicorandil )

  24. The ways of pharmacological therapy Addition of metabolites or cofactors • Activation of enzymes or complexes involving in generation of reduced equivalents, and their utilisation • Control of synthesis of mitochondrial factors, or genesis of mitochondria, and protection of mitochondria •   Improving Ph balance in the ischemic heart

  25. Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation Buenos Aires, Argentina The End Eugene Yevstratov E-mail Fax 001775 679 2870

More Related